Babak A. Ardekani1, 2, Laszlo Zaborszky3
1Center for Advanced Brain Imaging, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, United States; 2Department of Psychiatry, New York University School of Medicine, New York, United States; 3Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, NJ, United States
We propose the rate of change with time of the centroid size (S) of the mid-sagittal cross-sectional area of the corpus callosum as new biomarker that separates Alzheimers Disease (AD) from normal aging based on longitudinal structural MRI scans. Using data from the AD Neuroimaging Initiative (ADNI), we show that S increases with time in both normal aging and AD. However, the change in S is significantly greater in AD as compared to normal control subjects. Therefore, we suggest that change in S can be used as a reliable biomarker to predict conversion from mild cognitive impairment to AD.
Keywords